Insight Molecular Diagnostics (IMDX) financial statements
Insight Molecular Diagnostics reported revenue of $4M in fiscal 2025, up 27.2% a year over 5 years.
Net income was -$50M.
Free cash flow was -$25M.
The diluted share count rose 2198% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Insight Molecular Diagnostics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1M | $2M | $958,000 | $2M | $2M | $4M |
| Cost of revenue | — | — | — | — | $2M | $697,000 | $880,000 | $1M | $1M | $2M |
| Gross profit | — | — | — | — | -$639,000 | $1M | -$18,000 | $413,000 | $740,000 | $2M |
| Research and development | $6M | $7M | $7M | $7M | $10M | $5M | $7M | $9M | $10M | $16M |
| Selling, general and admin | $5M | $12M | $9M | $15M | $23M | $23M | $23M | $14M | $14M | $17M |
| Operating income | -$11M | -$19M | -$15M | -$22M | -$30M | -$54M | -$18M | -$25M | -$61M | -$51M |
| Interest expense | $0 | — | — | — | — | — | — | — | — | — |
| Pre-tax income | — | — | — | -$22M | -$31M | -$53M | -$19M | -$25M | -$61M | — |
| Income tax | — | — | — | — | -$1M | -$9M | — | $0 | $0 | $0 |
| Net income | -$11M | -$19M | -$16M | -$22M | -$30M | -$64M | -$73M | -$28M | -$61M | -$50M |
| EPS (diluted) | -$8.40 | -$12.80 | -$8.40 | -$8.80 | -$9.20 | -$14.40 | -$13.25 | -$3.75 | -$4.66 | -$1.65 |
| Diluted shares | 1M | 2M | 2M | 3M | 3M | 4M | 6M | 8M | 13M | 30M |
| Gross margin | — | — | — | — | -52.5% | 64.6% | -1.9% | 27.5% | 39.3% | 56.7% |
| Operating margin | — | — | — | — | -2443.3% | -2444.3% | -1878.6% | -1672.4% | -3245.1% | -1260.8% |
| Net margin | — | — | — | — | -2461.5% | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
Balance sheet
Fiscal years, from Insight Molecular Diagnostics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $10M | $8M | $8M | $22M | $7M | $33M | $20M | $9M | $9M | $12M |
| Receivables | — | — | — | — | $203,000 | $1M | $2M | $484,000 | $2M | $1M |
| Inventory | — | — | — | — | — | — | — | — | $410,000 | $446,000 |
| Total current assets | $13M | $9M | $9M | $23M | $9M | $39M | $26M | $11M | $12M | $15M |
| Property, plant and equipment | $688,000 | $822,000 | $614,000 | $4M | $4M | $7M | $9M | $5M | $6M | $6M |
| Goodwill | — | — | — | — | $9M | $19M | — | — | — | — |
| Total assets | $14M | $10M | $10M | $40M | $55M | $160M | $100M | $75M | $35M | $26M |
| Total current liabilities | $4M | $4M | $6M | $4M | $9M | $14M | $12M | $7M | $7M | $12M |
| Total liabilities | $5M | $6M | $6M | $9M | $22M | $94M | $60M | $49M | $47M | $57M |
| Shareholders' equity | $10M | $4M | $3M | $31M | $33M | $65M | $34M | $20M | -$12M | -$31M |
| Net debt | -$10M | -$8M | -$8M | -$22M | -$7M | -$33M | -$20M | -$9M | -$9M | -$12M |
Cash flow
Fiscal years, from Insight Molecular Diagnostics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8M | -$13M | -$12M | -$20M | -$26M | -$36M | -$46M | -$23M | -$21M | -$22M |
| Capital spending | $106,000 | $91,000 | $31,000 | $918,000 | $1M | $2M | $4M | $281,000 | $516,000 | $3M |
| Free cash flow | -$8M | -$13M | -$12M | -$21M | -$27M | -$38M | -$50M | -$24M | -$21M | -$25M |
| Stock-based compensation | $922,000 | $2M | $1M | $3M | $5M | $7M | $10M | $3M | $2M | $2M |
| Net borrowing | $0 | -$133,000 | -$800,000 | -$667,000 | $766,000 | -$2M | -$1M | — | — | — |
| Free cash flow margin | — | — | — | — | -2237.4% | -1737.4% | -5209.6% | -1570.6% | -1127.3% | -625.6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IMDX.
Open IMDX in InvestinglyQuestions
What was Insight Molecular Diagnostics's revenue in 2025?
$4M in fiscal 2025, from its 10-K filing.
How much free cash flow does Insight Molecular Diagnostics generate?
-$25M in fiscal 2025 (operating cash flow minus capital spending).
From Insight Molecular Diagnostics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.